정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 975 | Completed | Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B | Hemophilia B | Biological: Nonacog alfa | Phase 4 | Pfizer | INDUSTRY | 25 | Male | 12 Years ~ 65 Years | Nirmal Hospital, Surat, Gujarat, India K.J. Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India Sahyadri Clinical Research & Development Centre, Pune, Maharashtra, India Christian Medical College and Hospital, Ludhiana, Punjab, India Sahyadri Super Specialty Hospital, Pune, India |
| 974 | Recruiting | NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE | Sars-CoV2 | Drug: IgIV | Phase 2 | Versailles Hospital | OTHER | 35 | All | 75 Years | Centre Hospitalier de Versailles, Le Chesnay, France |
| 973 | Not yet recruiting | Northwest Therapies Trauma Psilocybin Study Compassionate Use Study | Trauma, Nervous System | Drug: Trauma | Phase 1 | NWTraumatherapies, Imperial College London, World Health Organization | NETWORK | 30 | All | 21 Years ~ 99 Years | Ross Allison NPI #1437519899 Administrator Of Study, Bozeman, Montana, United States |
| 972 | Active, not recruiting | Norwegian Coronavirus Disease 2019 Study | Corona Virus Infection | Drug: Hydroxychloroquine Sulfate | Phase 4 | University Hospital, Akershus | OTHER | 53 | All | 18 Years | Akershus University Hospital, Lørenskog, Norway |
| 971 | Not yet recruiting | Novaferon for COVID-19 Treatment Trial (NCTT-005) | Covid19 | Biological: Novaferon Biological: Placebo |
Phase 3 | Genova Inc. | INDUSTRY | 385 | All | 20 Years | |
| 970 | Recruiting | Novel Agents for Treatment of High-risk COVID-19 Positive Patients | Sars-CoV2 | Drug: Ivermectin Drug: Camostat Mesilate Dietary Supplement: Artemesia annua Drug: Artesunate |
Phase 2 | Susanne Arnold | OTHER | 240 | All | 18 Years ~ 99 Years | University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States |
| 969 | Not yet recruiting | Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | COVID-19 | Biological: Dental pulp mesenchymal stem cells | Early Phase 1 | CAR-T (Shanghai) Biotechnology Co., Ltd. | INDUSTRY | 24 | All | 18 Years ~ 75 Years |